collection
MENU ▼
Read by QxMD icon Read
search

artículos

shared collection
467 papers 100 to 500 followers
By César Gerardo Martínez Hernández General and Nuclear Cardiologist
https://www.readbyqxmd.com/read/29329384/plaque-erosion-a-new-in-vivo-diagnosis-and-a-potential-major-shift-in-the-management-of-patients-with-acute-coronary-syndromes
#1
Ramon A Partida, Peter Libby, Filippo Crea, Ik-Kyung Jang
Pathology and in vivo imaging studies have identified superficial plaque erosion as a frequent and important mechanism underlying acute coronary syndromes (ACS). In contrast with plaque rupture, the pathophysiological mechanisms leading to plaque erosion remain poorly understood. The advent of intravascular imaging techniques, particularly optical coherence tomography, has aided understanding of this mode of ACS in vivo by complementing previous insights from pathology studies. Appreciation of the distinct biological and clinical mechanisms of plaque erosion points to the possibility of tailored management strategies for patients presenting with ACS...
January 9, 2018: European Heart Journal
https://www.readbyqxmd.com/read/28454801/randomized-evaluation-of-the-effects-of-anacetrapib-through-lipid-modification-reveal-a-large-scale-randomized-placebo-controlled-trial-of-the-clinical-effects-of-anacetrapib-among-people-with-established-vascular-disease-trial-design-recruitment-and-baseline
#2
RANDOMIZED CONTROLLED TRIAL
L Bowman, F Chen, E Sammons, J C Hopewell, K Wallendszus, W Stevens, E Valdes- Marquez, S Wiviott, C P Cannon, E Braunwald, R Collins, M J Landray
Patients with prior vascular disease remain at high risk for cardiovascular events despite intensive statin-based treatment. Inhibition of cholesteryl ester transfer protein by anacetrapib reduces low-density lipoprotein (LDL) cholesterol by around 25% to 40% and more than doubles high-density lipoprotein (HDL) cholesterol. However, it is not known if these apparently favorable lipid changes translate into reductions in cardiovascular events. METHODS: The REVEAL study is a randomized, double-blind, placebo-controlled clinical trial that is assessing the efficacy and safety of adding anacetrapib to effective LDL-lowering treatment with atorvastatin for an average of at least 4years among patients with preexisting atherosclerotic vascular disease...
May 2017: American Heart Journal
https://www.readbyqxmd.com/read/29167102/coffee-consumption-and-health-umbrella-review-of-meta-analyses-of-multiple-health-outcomes
#3
REVIEW
Robin Poole, Oliver J Kennedy, Paul Roderick, Jonathan A Fallowfield, Peter C Hayes, Julie Parkes
Objectives To evaluate the existing evidence for associations between coffee consumption and multiple health outcomes.Design Umbrella review of the evidence across meta-analyses of observational and interventional studies of coffee consumption and any health outcome.Data sources PubMed, Embase, CINAHL, Cochrane Database of Systematic Reviews, and screening of references.Eligibility criteria for selecting studies Meta-analyses of both observational and interventional studies that examined the associations between coffee consumption and any health outcome in any adult population in all countries and all settings...
November 22, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28514624/evacetrapib-and-cardiovascular-outcomes-in-high-risk-vascular-disease
#4
RANDOMIZED CONTROLLED TRIAL
A Michael Lincoff, Stephen J Nicholls, Jeffrey S Riesmeyer, Philip J Barter, H Bryan Brewer, Keith A A Fox, C Michael Gibson, Christopher Granger, Venu Menon, Gilles Montalescot, Daniel Rader, Alan R Tall, Ellen McErlean, Kathy Wolski, Giacomo Ruotolo, Burkhard Vangerow, Govinda Weerakkody, Shaun G Goodman, Diego Conde, Darren K McGuire, Jose C Nicolau, Jose L Leiva-Pons, Yves Pesant, Weimin Li, David Kandath, Simon Kouz, Naeem Tahirkheli, Denise Mason, Steven E Nissen
BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease...
May 18, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29277252/2017-acc-expert-consensus-decision-pathway-for-optimization-of-heart%C3%A2-failure-treatment-answers-to-10%C3%A2-pivotal-issues-about-heart-failure-with-reduced-ejection-fraction
#5
Clyde W Yancy, James L Januzzi, Larry A Allen, Javed Butler, Leslie L Davis, Gregg C Fonarow, Nasrien E Ibrahim, Mariell Jessup, JoAnn Lindenfeld, Thomas M Maddox, Frederick A Masoudi, Shweta R Motiwala, J Herbert Patterson, Mary Norine Walsh, Alan Wasserman
No abstract text is available yet for this article.
December 13, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29244074/the-heart-regulates-the-endocrine-response-to-heart-failure-cardiac-contribution-to-circulating-neprilysin
#6
Mattia Arrigo, Nicolas Vodovar, Hélène Nougué, Malha Sadoune, Chris J Pemberton, Pamela Ballan, Pierre-Olivier Ludes, Nicolas Gendron, Alain Carpentier, Bernard Cholley, Philippe Bizouarn, Alain Cohen-Solal, Jagmeet P Singh, Jackie Szymonifka, Christian Latremouille, Jane-Lise Samuel, Jean-Marie Launay, Julien Pottecher, A Mark Richards, Quynh A Truong, David M Smadja, Alexandre Mebazaa
Aims: Heart failure (HF) is accompanied by major neuroendocrine changes including the activation of the natriuretic peptide (NP) pathway. Using the unique model of patients undergoing implantation of the CARMAT total artificial heart and investigating regional differences in soluble neprilysin (sNEP) in patients with reduced or preserved systolic function, we studied the regulation of the NP pathway in HF. Methods and results: Venous blood samples from two patients undergoing replacement of the failing ventricles with a total artificial heart were collected before implantation and weekly thereafter until post-operative week 6...
December 13, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28379800/body-weight-fluctuations-and-outcomes-in-coronary-disease
#7
RANDOMIZED CONTROLLED TRIAL
Sripal Bangalore, Rana Fayyad, Rachel Laskey, David A DeMicco, Franz H Messerli, David D Waters
BACKGROUND: Body-weight fluctuation is a risk factor for death and coronary events in patients without cardiovascular disease. It is not known whether variability in body weight affects outcomes in patients with coronary artery disease. METHODS: We determined intraindividual fluctuations in body weight from baseline weight and follow-up visits and performed a post hoc analysis of the Treating to New Targets trial, which involved assessment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with atorvastatin...
April 6, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29229783/heartbeat-what-is-the-best-emergency-treatment-for-decompensated-severe-aortic-stenosis
#8
Catherine M Otto
No abstract text is available yet for this article.
January 2018: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29229649/isolated-tricuspid-regurgitation-outcomes-and-therapeutic-interventions
#9
REVIEW
Erin A Fender, Chad J Zack, Rick A Nishimura
Isolated tricuspid regurgitation (TR) can be caused by primary valvular abnormalities such as flail leaflet or secondary annular dilation as is seen in atrial fibrillation, pulmonary hypertension and left heart disease. There is an increasing recognition of a subgroup of patients with isolated TR in the absence of other associated cardiac abnormalities. Left untreated isolated TR significantly worsens survival. Stand-alone surgery for isolated TR is rarely performed due to an average operative mortality of 8%-10% and a paucity of data demonstrating improved survival...
December 11, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29020969/updates-on-cardiovascular-outcome-trials-in-diabetes
#10
REVIEW
Oliver Schnell, Lars Rydén, Eberhard Standl, Antonio Ceriello
In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk...
October 11, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29156023/2017-esc-eacts-guidelines-for-the-management-of-valvular-heart-disease
#11
Volkmar Falk, Helmut Baumgartner, Jeroen J Bax, Michele De Bonis, Christian Hamm, Per Johan Holm, Bernard Iung, Patrizio Lancellotti, Emmanuel Lansac, Daniel Rodriguez Muñoz, Raphael Rosenhek, Johan Sjögren, Pilar Tornos Mas, Alec Vahanian, Thomas Walther, Olaf Wendler, Stephan Windecker, Jose Luis Zamorano
No abstract text is available yet for this article.
October 1, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28279666/pediatric-heart-failure-a-practical-guide-to-diagnosis-and-management
#12
REVIEW
Daniele Masarone, Fabio Valente, Marta Rubino, Rossella Vastarella, Rita Gravino, Alessandra Rea, Maria Giovanna Russo, Giuseppe Pacileo, Giuseppe Limongelli
Pediatric heart failure represents an important cause of morbidity and mortality in childhood. Currently, there are well-established guidelines for the management of heart failure in the adult population, but an equivalent consensus in children is lacking. In the clinical setting, ensuring an accurate diagnosis and defining etiology is essential to optimal treatment. Diuretics and angiotensin-converting enzyme inhibition are the first-line therapies, whereas beta-blockers and devices for electric therapy are less used in children than in adults...
August 2017: Pediatrics and Neonatology
https://www.readbyqxmd.com/read/29203195/2017-acc-expert-consensus-decision-pathway-on-management-of-bleeding-in-patients-on-oral-anticoagulants-a-report-of-the-american-college-of-cardiology-task-force-on-expert-consensus-decision-pathways
#13
Gordon F Tomaselli, Kenneth W Mahaffey, Adam Cuker, Paul P Dobesh, John U Doherty, John W Eikelboom, Roberta Florido, William Hucker, Roxana Mehran, Steven R Messé, Charles V Pollack, Fatima Rodriguez, Ravindra Sarode, Deborah Siegal, Barbara S Wiggins
No abstract text is available yet for this article.
December 19, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29186485/indications-and-practical-approach-to-non-invasive-ventilation-in-acute-heart-failure
#14
Josep Masip, W Frank Peacock, Susanna Price, Louise Cullen, F Javier Martin-Sanchez, Petar Seferovic, Alan S Maisel, Oscar Miro, Gerasimos Filippatos, Christiaan Vrints, Michael Christ, Martin Cowie, Elke Platz, John McMurray, Salvatore DiSomma, Uwe Zeymer, Hector Bueno, Chris P Gale, Maddalena Lettino, Mucio Tavares, Frank Ruschitzka, Alexandre Mebazaa, Veli-Pekka Harjola, Christian Mueller
In acute heart failure (AHF) syndromes significant respiratory failure (RF) is essentially seen in patients with acute cardiogenic pulmonary oedema (ACPE) or cardiogenic shock (CS). Non-invasive ventilation (NIV), the application of positive intrathoracic pressure through an interface, has shown to be useful in the treatment of moderate to severe RF in several scenarios. There are two main modalities of NIV: continuous positive airway pressure (CPAP) and pressure support ventilation (NIPSV) with positive end expiratory pressure...
November 26, 2017: European Heart Journal
https://www.readbyqxmd.com/read/29190377/european-society-of-cardiology-cardiovascular-disease-statistics-2017
#15
Adam Timmis, Nick Townsend, Chris Gale, Rick Grobbee, Nikos Maniadakis, Marcus Flather, Elizabeth Wilkins, Lucy Wright, Rimke Vos, Jeroen Bax, Maxim Blum, Fausto Pinto, Panos Vardas
Aims: The European Society of Cardiology (ESC) Atlas has been compiled by the European Heart Agency to document cardiovascular disease (CVD) statistics of the 56 ESC member countries. A major aim of this 2017 data presentation has been to compare high-income and middle-income ESC member countries to identify inequalities in disease burden, outcomes, and service provision. Methods and results: The Atlas utilizes a variety of data sources, including the World Health Organization, the Institute for Health Metrics and Evaluation, and the World Bank to document risk factors, prevalence, and mortality of cardiovascular disease and national economic indicators...
November 27, 2017: European Heart Journal
https://www.readbyqxmd.com/read/29158679/treatment-of-pulmonary-hypertension-with-left-heart-disease-a-concise-review
#16
REVIEW
Anish Desai, Shilpa A Desouza
Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure ≥ 25 mmHg, as determined by right heart catheterization. Pulmonary arterial hypertension (PAH) can no longer be considered an orphan disease given the increase in awareness and availability of new drugs. PH carries with it a dismal prognosis and leads to significant morbidity and mortality. Symptoms can range from dyspnea, fatigue and chest pain to right ventricular failure and death. PH is divided into five groups by the World Health Organization (WHO), based on etiology...
2017: Vascular Health and Risk Management
https://www.readbyqxmd.com/read/29150426/long-term-outcomes-in-patients-with-type-2-myocardial-infarction-and-myocardial-injury
#17
Andrew R Chapman, Anoop S V Shah, Kuan Ken Lee, Atul Anand, Oliver Francis, Philip Adamson, David A McAllister, Fiona Strachan, David E Newby, Nicholas L Mills
Background -Type 2 myocardial infarction and myocardial injury are common in clinical practice, but long-term consequences are uncertain. We aimed to define long-term outcomes and explore risk stratification in patients with type 2 myocardial infarction and myocardial injury. Methods -We identified consecutive patients (n=2,122) with elevated cardiac troponin I concentrations (≥0.05 μg/L) at a tertiary cardiac center. All diagnoses were adjudicated as per the Universal Definition of Myocardial Infarction...
November 17, 2017: Circulation
https://www.readbyqxmd.com/read/29130810/outcomes-after-angiography-with-sodium-bicarbonate-and-acetylcysteine
#18
Steven D Weisbord, Martin Gallagher, Hani Jneid, Santiago Garcia, Alan Cass, Soe-Soe Thwin, Todd A Conner, Glenn M Chertow, Deepak L Bhatt, Kendrick Shunk, Chirag R Parikh, Edward O McFalls, Mary Brophy, Ryan Ferguson, Hongsheng Wu, Maria Androsenko, John Myles, James Kaufman, Paul M Palevsky
Background Intravenous sodium bicarbonate and oral acetylcysteine are widely used to prevent acute kidney injury and associated adverse outcomes after angiography without definitive evidence of their efficacy. Methods Using a 2-by-2 factorial design, we randomly assigned 5177 patients at high risk for renal complications who were scheduled for angiography to receive intravenous 1.26% sodium bicarbonate or intravenous 0.9% sodium chloride and 5 days of oral acetylcysteine or oral placebo; of these patients, 4993 were included in the modified intention-to-treat analysis...
November 12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29146535/2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-prevention-detection-evaluation-and-management-of-high-blood-pressure-in-adults-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice
#19
Paul K Whelton, Robert M Carey, Wilbert S Aronow, Donald E Casey, Karen J Collins, Cheryl Dennison Himmelfarb, Sondra M DePalma, Samuel Gidding, Kenneth A Jamerson, Daniel W Jones, Eric J MacLaughlin, Paul Muntner, Bruce Ovbiagele, Sidney C Smith, Crystal C Spencer, Randall S Stafford, Sandra J Taler, Randal J Thomas, Kim A Williams, Jeff D Williamson, Jackson T Wright
No abstract text is available yet for this article.
November 7, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28944172/surgical-treatment-for-hypertrophic-cardiomyopathy-a-historical-perspective
#20
REVIEW
Dustin Hang, Anita Nguyen, Hartzell V Schaff
Our understanding of hypertrophic cardiomyopathy (HCM) as a disease entity has increased dramatically over the last half century. There has been a concerted effort by several surgical groups to develop operative techniques to relieve left ventricular outflow tract (LVOT) obstruction and alleviate symptoms. This paper traces the development of transaortic septal myectomy, the current gold standard therapy for relief of LVOT obstruction, in symptomatic patients refractory to medical treatment. In addition, we introduce newer methods for myectomy that have expanded the role of surgery in patients with various forms of HCM...
July 2017: Annals of Cardiothoracic Surgery
label_collection
label_collection
5014
1
2
2017-11-19 18:04:55
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"